HYDROXYCHLOROQUINE TABLET

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

HYDROXYCHLOROQUINE SULFATE

Disponible des:

SANIS HEALTH INC

Codi ATC:

P01BA02

Designació comuna internacional (DCI):

HYDROXYCHLOROQUINE

Dosis:

200MG

formulario farmacéutico:

TABLET

Composición:

HYDROXYCHLOROQUINE SULFATE 200MG

Vía de administración:

ORAL

Unidades en paquete:

15G/50G

tipo de receta:

Prescription

Área terapéutica:

ANTIMALARIALS

Resumen del producto:

Active ingredient group (AIG) number: 0107403001; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2021-08-26

Fitxa tècnica

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
HYDROXYCHLOROQUINE
Hydroxychloroquine Sulfate Tablets
Tablets, 200 mg, Oral
USP
Anti-Inflammatory – Antimalarial – Aminoquinolines
Sanis Health Inc.
1 President's Choice Circle
Brampton, Ontario
L6Y 5S5
Date of Initial Authorization:
AUG 26, 2021
Date of Revision:
JUL 19, 2023
Submission Control Number: 276674
_HYDROXYCHLOROQUINE (hydroxychloroquine sulfate tablets _
_Page 2 of 43 _
_ _
RECENT MAJOR LABEL CHANGES
2 Contraindications
08/2021
4 Dosage and Administration, Pregnant Women
02/2022
7 Warnings and Precautions, Hematologic
02/2022
7 Warnings and Precautions, Musculoskeletal
02/2022
7 Warnings and Precautions, Psychiatric
02/2022
7 Warnings and Precautions, Skin
03/2023
7 Warnings and Precautions, 7.1.1 Pregnant Women
02/2022
7 Warnings and Precautions, 7.1.4 Geriatrics
02/2022
7 Warning and Precautions, Cardiovascular
07/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
CONTRAINDICATIONS
.................................................................................................
5
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations:
................